Portfolio Company Cerecin Enrolls First Patient in a Pilot Clinical Trial of Tricaprilin…
페이지 정보
작성자 KNTinvestment 댓글 0건 조회 3,603회 작성일 21-11-24 11:54본문
SINGAPORE and DENVER, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cerecin, a clinical-stage biotechnology company developing ketogenic agents as potential neurotherapeutics, today announced the enrollment of the first patient in its AC-21-024 study, a pilot clinical trial of tricaprilin for the treatment of Infantile Spasms. Tricaprilin is an investigational oral drug under development for several neurological conditions, including migraine and epilepsy, and is designed to induce ketosis. In October 2020, Cerecin received Rare Pediatric Disease Designation and Orphan Drug Designation for tricaprilin in Infantile Spasms from the U.S. Food and Drug Administration.
The AC-21-024 clinical trial investigates the feasibility, safety, tolerability, and efficacy of daily administration of tricaprilin in participants with Infantile Spasms. The study is being conducted at leading institutions for pediatric epilepsy in Australia and Singapore and results are expected in late 2022.
Dr. Judith Walker, Cerecin’s Chief Medical Officer, said, “Infantile Spasms is a serious condition, and is frequently neglected by biopharma companies. Infantile Spasms is seen in around 1 in every 3,000 infants globally and has unmet clinical needs. We are optimistic about the potential of tricaprilin as a treatment for this devastating epileptic condition of childhood.”
For more information on our Infantile Spasms trial, see www.clinicaltrials.gov, identifier NCT04727970 , or please visit www.cerecinresearch.com.
About Cerecin
Cerecin is a biopharmaceutical company focused on the discovery and development of drugs to treat and prevent diseases of the brain. Cerecin’s development programmes leverage its extensive experience in lipid science to explore the potential therapeutic benefits of ketogenic drugs and other compounds in a variety of conditions. Cerecin is led by an expert executive management team with strong global expertise in central nervous system drug development and is supported by two partners, Nestlé, and Wilmar, one of the world’s leading manufacturers of fatty acids and lipids. In addition to the AC-21-024 study of tricaprilin in Infantile Spasms, Cerecin is currently conducting study AC-20-022 of tricaprilin in migraine prevention (NCT04437199 (The RELIEF trial)). Bringing together the deep industry expertise of its leadership team, and a highly differentiated drug development program, Cerecin is becoming a global leader in neurology therapeutics.
About Infantile Spasms
Infantile Spasms (IS) is a pediatric epileptic condition characterized by epileptic spasms, an abnormal brain wave pattern called hypsarrhythmia, and developmental delay, presenting in infancy. It is commonly treated with ACTH and vigabatrin, as well as a ketogenic diet.
For further information, please contact:
Khushboo Tanna / Hannah Crowe
cerecin@spurwingcomms.com
© 2021 Cerecin AC-21-940 10/21
The AC-21-024 clinical trial investigates the feasibility, safety, tolerability, and efficacy of daily administration of tricaprilin in participants with Infantile Spasms. The study is being conducted at leading institutions for pediatric epilepsy in Australia and Singapore and results are expected in late 2022.
Dr. Judith Walker, Cerecin’s Chief Medical Officer, said, “Infantile Spasms is a serious condition, and is frequently neglected by biopharma companies. Infantile Spasms is seen in around 1 in every 3,000 infants globally and has unmet clinical needs. We are optimistic about the potential of tricaprilin as a treatment for this devastating epileptic condition of childhood.”
For more information on our Infantile Spasms trial, see www.clinicaltrials.gov, identifier NCT04727970 , or please visit www.cerecinresearch.com.
About Cerecin
Cerecin is a biopharmaceutical company focused on the discovery and development of drugs to treat and prevent diseases of the brain. Cerecin’s development programmes leverage its extensive experience in lipid science to explore the potential therapeutic benefits of ketogenic drugs and other compounds in a variety of conditions. Cerecin is led by an expert executive management team with strong global expertise in central nervous system drug development and is supported by two partners, Nestlé, and Wilmar, one of the world’s leading manufacturers of fatty acids and lipids. In addition to the AC-21-024 study of tricaprilin in Infantile Spasms, Cerecin is currently conducting study AC-20-022 of tricaprilin in migraine prevention (NCT04437199 (The RELIEF trial)). Bringing together the deep industry expertise of its leadership team, and a highly differentiated drug development program, Cerecin is becoming a global leader in neurology therapeutics.
About Infantile Spasms
Infantile Spasms (IS) is a pediatric epileptic condition characterized by epileptic spasms, an abnormal brain wave pattern called hypsarrhythmia, and developmental delay, presenting in infancy. It is commonly treated with ACTH and vigabatrin, as well as a ketogenic diet.
For further information, please contact:
Khushboo Tanna / Hannah Crowe
cerecin@spurwingcomms.com
© 2021 Cerecin AC-21-940 10/21